¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"activity, drug"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • synthetic drug
    ÇÕ¼º¾à
  • topical drug
    ±¹¼Ò¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • vasoactive drug
    Ç÷°üÀÛ¿ë¾à
  • fixed drug eruption
    °íÁ¤¾à¹°¹ßÁø
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¾à¹°¹ßÁø
  • generic drug name
    ÀϹݾà¸í
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • transdermal drug delivery system
    °æÇǾ๰Àü´Þü°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • drug
    ¾à¹°(å·Úª)
  • drug (induced) allergy
    ¾à¹°(À¯¹ß) ¾Ë·¹¸£±â.
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü(Ð×Ó¨).
  • drug abuse
    ¾à¹° ³²¿ë
  • drug abuse
    ¾à¹°³²¿ë
  • drug abuse
    ¾à¹°³²¿ë(å·ÚªÕ½éÄ).
  • drug acne<³ª> a. medicamentesa
    ¾à¹°¼º(å·Úªàõ) ¿©µå¸§.
  • drug acne<³ª>a medicamentesa
    ¾à¹°¼º(å·Úªàõ)¿©µå¸§
  • drug action
    ¾à¹°ÀÛ¿ë(¡­íÂéÄ)
  • drug action
    ¾à¹°ÀÛ¿ë(¡­íÂéÄ).
  • drug addiction
    ¾à¹°½À°ü¼º Áßµ¶(å·Úªã§Î±àõñéÔ¸).
  • drug addiction
    ¾à¹°½À°ü¼º Áßµ¶(å·Úªã§Î±àõñéÔ¸).
  • drug addiction
    ¾à¹°»ó½À(¡­ßÈã§)
  • drug adjuvant
    ÀǾàǰ÷°¡¹°(ì¢å·ù¡ôÕÊ¥Úª).
  • drug adsorption
    ¾à¹°ÈíÂø
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
AL absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru...
AMA-DE American Medical Association Drug Evaluation
AMSAODD American Medical Society on Alcoholism and Other Drug Dependencies
ANDA Abbreviated New Drug Application
AODP alcohol and other drug problems
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
IDU Intravenous drug users
IND Investigational New Drug
IND Investigational New Drug Application
MDR Multi drug resistance
MDT Multi drug therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • long acting drug
    Áö¼Ó¼º ¾à
  • metabolic drug
    ´ë»ç ¾à¹°
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ¾àǰ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • multiple drug misuse
    ¿©·¯ ¾à¹°ÀÇ ¿À¿ë
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • narcotic drug
    ¸¶¾à
    ¸ð¸£ÇÉ, ÄÚÄ«ÀÎ, ¾ÆÆí µî°ú ±× À¯µµÃ¼·Î¼­ ¹Ì·®À¸·Î °­·ÂÇÑ ÁøÅë ÀÛ¿ë°ú ¸¶Ãë ÀÛ¿ëÀ» Áö´Ï¸ç °è¼Ó »ç¿ëÇÏ¸é ½À°ü¼º°ú Ž´Ð¼ºÀÌ »ý±â°Ô ÇÏ´Â ¹°Áú. »ç¿ëÀ» Áß´ÜÇÏ¸é °Ý·ÄÇÑ ±Ý´Ü Áõ¼¼¸¦ ÀÏÀ¸ÄÑ ¸¶¾àÀ» »ç¿ëÇÏÁö ¾Ê°í´Â Á¤»óÀûÀÎ »ýȰÀ» ÇÒ ¼ö ¾ø°Ô µÇ¸ç, Á¾±¹¿¡ °¡¼­´Â À°Ã¼ÀûÀ¸·Î³ª Á¤½ÅÀûÀ¸·Î ÆóÀÎÀÌ µÇ°Ô ÇÏ´Â ¹°ÁúÀÌ´Ù. ÀÌ·± ¹°ÁúÀÌ ÀÇ·á ¹× ¿¬±¸ ÀÌ¿ÜÀÇ ¸ñÀû¿¡ ³²¿ëµÇ´Â À§ÇèÀ» ¹æÁöÇϱâ À§ÇÏ¿© Á¤ÇÑ ¹ý·ü»ó ¿ë¾î°¡ ¸¶¾àÀÌ´Ù. ¸¶¾àÀº ¨ç ¾Þ¼Ó¿¡¼­ äÃëÇÏ´Â ¾ÆÆí ¾ËÄ®·ÎÀ̵å°è ¸¶¾à
  • negative drug history
    À½¼º Åõ¾à º´·Â
  • neuroleptic drug
    ½Å°æ ÀÌ¿ÏÁ¦
  • new drug application
    ½Å¾à Çã°¡ ½Åû
  • non-respiratory depressant drug
    ºñ-È£Èí ¾ïÁ¦Á¦
  • orphan drug
    Èñ±Ô ÀǾàǰ
  • OTC drug
    ÀÏ¹Ý ¸Å¾à
    over-the-counter drugÀÇ ¾àÀÚ. ÀÇ»çÀÇ Ã³¹æÀÌ ¾øÀÌ ¾à±¹¿¡¼­ ±¸ÇÒ ¼ö ÀÖ´Â ¾à.
  • poisoning by drug
    ¾à¹° Áßµ¶
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 9
orphan drug A pharmaceutical that has been abandoned or neglected during its development because it is seen as having only a limited potential for profit. Often a drug which only has a limited target population or which treats a rare disease, thus limiting its financial potential.
(09 Oct 1997)
orphan drug act Law giving incentives to companies developing a drug for a rare disease. The act gives the developer of the first drug of any one type a 7-year exclusive right to market the new drug.
(14 Nov 1997)
orphan drug production Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.
(12 Dec 1998)
targeted drug delivery Delivering a drug to a specific site in the body where it has the greatest effect, instead of allowing it to diffuse to various sites, where it may cause damage or trigger side effects.
(14 Nov 1997)
united states food and drug administration An agency of the public health service concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
(12 Dec 1998)
fixed drug eruption A type of drug eruption that recurs at a fixed site (or sites) following the administration of a particular drug; the lesions usually consist of intensely erythematous and purplish, sharply demarcated macules, and occasionally of herpetic vesicles; the affected areas undergo gradual involution, but flare and enlarge on readministration of the offending drug and may become hyperpigmented.
Iodine eruption, an acneform or follicular eruption or granulomatous lesion caused by a reaction to systemic iodine or iodide administration.
Kaposi's varicelliform eruption, a now rare complication of vaccinia superimposed on atopic dermatitis, with generalised vesicles and vesicopapules and high fever.
Synonym: eczema vaccinatum.
(05 Mar 2000)
food and drug administration The U.S. Agency responsible for regulation of biotechnology foodproducts. The major laws under which the agency has regulatory powersinclude the Food, Drug, and Cosmetic act, and the Public Health Service Act.
(09 Oct 1997)
food-drug interactions The pharmacological result, either desirable or undesirable, of drugs interacting with components of the diet.
(12 Dec 1998)
legislation, drug Laws concerned with manufacturing, dispensing, and marketing of drugs.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á